| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2765500 | Journal of Critical Care | 2010 | 8 Pages |
Abstract
Patients receiving drotrecogin alfa (activated) in clinical practice were more acutely ill, had a higher mortality rate, but a similar safety profile with respect to serious bleeding events compared to the PROWESS trial.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jay S. MD, Michael L. MD, Brad MD, H. Tiffany MS, Mark B. MD, for the XEUS investigators for the XEUS investigators,